Rapid Microbiological Method to Dominate the Bioburden Testing Market: Fact.MR

Unites States to Create Lucrative Opportunities for Bioburden Testing Market – Fact.MR Study

Fact.MR – A Market Research and Competitive Intelligence Provider: During the forecast period 2021-2031, the global bioburden testing market is expected to develop at a healthy rate. The market will rise due to the need for faster and more accurate bioburden testing systems, according to a recent Fact.MR analysis.

Conventional culture-based microbiology procedures have a lengthier turnaround time and are prone to erroneous results, according to a medical journal published in the US National Library of Medicine - National Institutes of Health, generating inefficiencies in the workflow.

Because of the time lag associated with current testing methods, a desire for faster, safer, and more accurate bioburden testing systems has emerged, creating fertile ground for bioburden testing market participants.

For Critical Insights On This Market, Request For More Info

https://www.factmr.com/connectus/sample?flag=B&rep_id=6304

The COVID-19 pandemic has posed unprecedented hurdles to the market, as a lack of supplies has hampered everyday laboratory activities, resulting in a considerable reduction in overall testing capacity. However, when the world progressively returns to a pre-pandemic state, the market is likely to increase at a healthy rate, according to Fact.MR.

During the projected period, North America will continue to dominate the bioburden testing market. According to Savills Research, around 63% of life science capital was raised by companies based in the United States.

With the United States expected to continue to dominate life science corporate investment volume, demand for bioburden testing in North America will grow at a healthy rate.

“Increasing product and device recalls due to contamination and rapid shift towards digitization will fuel demand for bioburden testing to minimize complications witnessed by laboratory experts,” says the Fact.MR analyst.

Key Takeaways:

  • In the bioburden testing market, the rapid microbiological method (RMM) has emerged as a leading method.
  • Market prospects in the United States appear to be good, thanks to increased investments in the life science corporate sector.
  • Increased spending in Europe's life science sector, combined with the presence of a sophisticated healthcare infrastructure, will boost sales.
  • Bioburden testing will be in great demand among pharmaceutical and biotechnology industries.

Key Drivers

  • Demand for bioburden testing will be fueled by regulations set by various governments to encourage the use of microbial contamination prevention techniques.
  • As the world becomes more digital, the demand for technologically enhanced testing methods will rise, giving opportunity for market players.
  • As a result of increased contamination concerns, product recalls will motivate players to develop more effective products, boosting market growth.

Key Restraints:

  • Failure to eliminate existing limitations in the new products will negatively affect the market growth.
  • Market sales will be impacted by high production costs and a lack of research and development in the sector.
  • Lower investment in healthcare infrastructure and the life sciences sector will have a detrimental influence on market growth.


To learn more about Bioburden Testing Market, you can get in touch with our Analyst at

https://www.factmr.com/connectus/sample?flag=AE&rep_id=6304

Competitive Landscape


Some of the key players operating in the bioburden testing market are Thermo Fisher Scientific Inc., Merck KGaA, Steris, Becton, Dickinson and Company, Pacific BioLabs, Nelson Laboratories LLC, Biomérieux SA, Charles River, Rapid Micro Biosystems Inc., ViroxySdn. Bhd.

Various inorganic strategies adopted by leading pharmaceutical and biotechnological players have positively affected the market growth. The key players operating in the market are focusing on expanding their products and services, along with improvements in lab productivity. For instance:

  • In March 2021, Rapid Micro Biosystems announced its investment of around US$81 Mn in equity financing to boost its global expansion of Automated pharmaceutical QC Platform.

More Valuable Insights on Bioburden Testing Market

Fact.MR, in its new report, offers an unbiased analysis of the global bioburden testing market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on insulin delivery devices market with detailed segmentation:

By Product

  • Consumables
    • Culture Media
    • Reagents
    • Pipette
    • Media cassettes
    • Kits
    • Ampoule
    • Other
  • Instruments
    • Microscopes
    • Filtration system
    • Automated Microbial Identification Systems
    • PCR
    • Incubator
    • Others

By Test Type

  • Anaerobic Count Testing
  • Aerobic Count Testing
  • Spores Count Testing
  • Fungi/Mold Count Testing

By Method

  • Rapid Microbiological Method (RMM)
    • Growth Direct System Method
    • Automated detection of growth
    • Auto fluorescence I
    • Auto fluorescence II
    • ATP-Bioluminescence
    • Cytometry
    • Endotoxin
  • Membrane filtration
  • Plate count method or MPN

By Application

  • Raw Material Testing
  • In-process Testing
  • Sterilization Validation Testing
  • Medical devises Testing
  • Equipment Cleaning Validation

By End-Use Industry

  • Pharmaceutical and Biotechnology Companies
  • Medical Device Companies
  • Microbial Testing Laboratories
  • Contract Manufacturing Organizations (CMOS)
  • Food & Beverage Industry

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East Africa

Explore Fact. MR’s Coverage on the Healthcare Domain-


Immunoassay Market Analysis - The global immunoassays market is expected to grow at a rapid pace. For the diagnosis of infectious disorders, immunoassay analyzers such as enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and immunofluorescence assay (IFA) are chosen.

PCR and Real-time PCR Molecular Diagnostics Market - The COVID-19 pandemic has boosted prospects for the growth of the PCR and real-time PCR molecular diagnostics market. Real-time (qPCR) and digital (dPCR) PCR tests have been used in a variety of healthcare settings to detect and diagnose potential cases

Rapid Medical Diagnostic Kits Market Forecast - Infectious disease incidence has been steadily increasing over the last few decades, driving up demand for rapid medical diagnostic kits around the world. The need to detect novel pathogens that cause diseases is propelling the market forward. The low cost of rapid medical diagnostic kits is propelling market growth.

Predictive Diagnostics Market Insights - Predictive diagnostics is one strategy that healthcare organizations can use to improve outcomes while lowering costs. The use of predictive diagnostics is predicted to revolutionize the way the healthcare industry works, thanks to improvements in data-based technology and their convergence with healthcare practices.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to chemical and materials, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.


MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.
 

You can access all our chemical and materials research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.

Contact:

Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
 

Source: Fact.MR

Back to news